• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Diagnosis and Acute Treatment of Ischemic Stroke
Rev Recent Clin Trials. 2022 Jun 17. doi: 10.2174/1574887117666220617103114. Online ahead of print.ABSTRACTStroke is defined as an acute cerebrovascular accident characterized by an interruption of vascular supply lasting more than 24 hours. Therapeutic goal, reassumed at the well-known "time is brain", is strictly focused on achieving timely restoration of cerebral blood flow at risk of infarction to reduce neurological complications. Consequently, time to treatment is the most important determinant of the efficacy of reperfusion. Current guidelines strongly recommend the use of intravenous thrombolysis with tissue plasmi...
Source: Reviews on Recent Clinical Trials - June 20, 2022 Category: Cancer & Oncology Authors: Ernesto Cristiano Lauritano Federica Nicoletta Sepe Maria Carmela Mascolo Riccardo Boverio Luigi Ruiz Source Type: research

The Gut Microbiota-Brain Axis in Acute Neurological Disease: Focus on Stroke
Rev Recent Clin Trials. 2022 Mar 21. doi: 10.2174/1574887117666220321155508. Online ahead of print.ABSTRACTThe gut microbiota is one of the great innovations of modern medicine. In the modern microbiota revolution era, more comprehensive and in-depth studies have been performed as regards the microbial gut communities and their impact on acute and chronic diseases, including those of the nervous system as acute neurological diseases. The microbiota has changed our knowledge of medical conditions; in particular, considering stroke (both ischemic and hemorrhagic), literature studies, experimental and clinical researches indi...
Source: Reviews on Recent Clinical Trials - March 23, 2022 Category: Cancer & Oncology Authors: Saviano Angela Gayani Gunawardena Zanza Christian Longhitano Yaroslava Migneco Alessio Candelli Marcello Franceschi Francesco Ojetti Veronica Source Type: research

A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding.
CONCLUSION: Although these agents have been marketed for five years (idarucizumab) and two years (andexanet alfa) respectively, and despite guidelines considering antidotes as first-line agents in treating life-threatening hemorrhage when available, these antidotes seem to gain access very slowly in the clinical practice. Cost, logistical aspects and need for plasma level determination of DOAC for an accurate therapeutic use probably have an impact on this phenomenon.. An expert multidisciplinary bleeding team should be established so as to implement international guidelines based on local resources and organization. ...
Source: Reviews on Recent Clinical Trials - June 23, 2020 Category: Cancer & Oncology Authors: Ojetti V, Saviano A, Brigida M, Saviano L, Migneco A, Franceschi F Tags: Rev Recent Clin Trials Source Type: research

New Alternative Anticoagulants in Atrial Fibrillation: The Move Beyond Warfarin.
Abstract Given the increasing prevalence of atrial fibrillation, the need for safe and effective stroke prophylaxis will continue to rise. Warfarin has been around for many years and has proven efficacy in preventing stroke, but it has major limitations due to its variable dosing, food and drug interactions, and requirement for regular monitoring. Newer agents which include dabigatran, rivaroxaban, and apixaban have recently or will soon be available and may provide an improved efficacy in stroke prevention, an improved safety profile, and improved user-friendliness. Dabigatran was the first of the agents to be wi...
Source: Reviews on Recent Clinical Trials - July 5, 2013 Category: Cancer & Oncology Authors: Bhimani AA, Hong M Tags: Rev Recent Clin Trials Source Type: research